Radiation Dermatitis Treatment Market
Radiation Dermatitis Treatment Market Analysis Report By Product (Oral Medication-based Radiation Dermatitis Treatment, Topical Radiation Dermatitis Treatment, Dressing-based Radiation Dermatitis Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Regional Forecast 2021-2031
Radiation Dermatitis Treatment Industry Snapshot
The global radiation dermatitis treatment market to register a high market value, reaching US$ 700 Mn by the end of the 2021-2031 assessment period, registering a CAGR of 5%. In the short-run, by 2021-end, sales of radiation dermatitis products are likely to close in at US$ 429.7 Mn. High demand is anticipated for topical hydrophilic creams, likely to yield 33% of global market revenue.
|Market Value (2021)||US$ 429.7 Mn|
|Projected Market Valuation (2031)||US$ 700 Mn|
|Growth Rate (2021-2031)||5% CAGR|
Demand Analysis of Radiation Dermatitis Treatment 2016-2020 Vs Future Outlook 2021-2031
Recent estimates from Fact.MR- a market research & competitive intelligence provider- establishes that demand for radiation dermatitis treatment accelerated at a steady pace from 2016-2020, registering a CAGR worth 4% amid rising frequencies of advanced radiation-based treatment for different grades of cancers.
During the worst of COVID-19, prospects for radiation dermatitis treatment declined considerably, especially across hospitals and clinics, attributed to increased apprehensions about transmitting the novel coronavirus to patients. At the same time, home based treatment in the form of topical creams available at online and retail stores increased.
Future growth prospects are reliant on the incorporation of biocompatible and nanoparticle compounds, which include self-healing and antimicrobial properties. Based on all aforementioned trends, it is evident that the global market for radiation dermatitis treatment is expected to register positive growth, clocking a CAGR of 5% from 2021-2031.
How is Rising Prevalence of Cancer Driving Demand for Radiation Dermatitis Treatment?
According to the International Agency for Cancer Research (IARC), the number of new cancer cases rose to 19.3 million, with 10 million deaths during the year. By 2040, this number shall surpass 29 million, while deaths will increase to more than 16 million. Consequently, patients are seeking radiation treatment as it is highly effective in eradicating some of the worst cancers.
While radiation therapy accounts for 40% of all cancer cures globally, studies have indicated that patients receiving them are at heightened risk of suffering from radiation burns which induce numerous skin problems. Hence, uptake of radiation dermatitis dressings and treatment products is inclining across key regions.
What Prospects are in Store for Biocompatible & Biodegradable Nanomaterials?
Manufacturers are bolstering production capacities in wound dressings which are highly elastic and flexible. However, it has been found that these dressings in some cases may damage fragile skin and may not prevent maceration.
This has created a need for new biocompatible and biodegradable nanomaterials that help in regulating all phases of wound healing. Companies in the radiation dermatitis treatment market are increasing their R&D capabilities to develop dressings that incorporate antibacterial and self-healing properties.
Avail customized purchase options for your needs
How are Alternative Radiation Therapies Catalyzing Growth Prospects?
Modern radiotherapy techniques, which include intensity-modulated radiation therapy (IMRT) and proton therapy, can diminish the risk for radiation dermatitis by more accurately targeting tumor, thereby saving the normal tissue from repeated assault.
Higher adoption of these techniques, especially in developed regions, as they result in fewer severe rated cases of radiation dermatitis. This is likely to restrain uptake of chronic radiation dermatitis treatment products to a significant extent.
Surging Skin Cancer Treatment Impelling Radiation Dermatitis Treatment in the U.S?
According to the Skin Cancer Foundation, over 9,500 people in the U.S are diagnosed with skin care daily, with over 2/3rd of the people succumbing every hour. More than 5.4 million cases of non-melanoma skin cancer were treated in over 3.3 million people in 2012. Also, at least one in five Americans will develop skin cancer by the age of 70.
Hence, the scope for radiation dermatitis has increased in recent years. As per the American Society for Radiation Oncology (ASTRO), nearly 95% of patients receiving radiation therapy suffer from some degree of radiation dermatitis, thus requiring treatment for the same, which is broadening avenues for the market.
Numerous topical steroid creams and oral medication manufacturers have flourished in the U.S market for radiation dermatitis treatment in recent years. For instance, AdvaCare Pharma offers the CortiCareTM Hydrocortisone Ointment, which helps reduce inflammation, redness and swelling. Similarly, the 3MTM CavilonTM No Sting Barrier Film offers a sting-free formula which forms a transparent barrier over the skin, protecting it from friction and aids in moisture management. Based on these developments, the market in the U.S will likely surge at a CAGR of 5.3% until 2031.
How is Treatment for Breast Cancer Augmenting Prospects across India?
According to Fact.MR, radiation dermatitis treatment products sales in India are expected to register a CAGR worth 6% across the 2021-2031 forecast period. While numerous skin cancer treatment approaches are widening its scope, treatment for breast cancer in particular is expected to provide major tailwinds to market growth.
According to statistics published by Cytecare Cancer Hospitals, breast cancer accounts for 14% of cancers in Indian women. Every four minutes, an Indian woman is diagnosed with breast cancer. The incidence is especially high across the metro cities, account for over 1/4th of all female cancers. Hence, patients are seeking advanced radiation based treatment.
Overall incidence of grade 1-2 acute erythematous reactions resulting from radiation based treatment is 80-90%, while moist desquamation is observed in around 10-15% of the patients. Some studies have reported increased grade 1-2 late fibrosis in patients undergoing breast conservation surgery and hypo fractionated radiotherapy.
Will China Be a Lucrative Market for Radiation Dermatitis Treatment?
China is likely to offer highly attractive growth prospects, attributing to the ever-widening popularity of Traditional Chinese Medicine (TCM). TCM holds promising potentials in minimizing the impact of radio-dermatitis in patients with neck and head cancer. A CAGR of 5.8% is projected for the Chinese market.
Companies in the acute radiation dermatitis treatment market are capitalizing on this opportunity to innovate in pastes that improve the symptoms of skin reaction caused due to radiotherapy. Honeysuckle is emerging as one of the key ingredients in TCM for the treatment of carbuncles, while medicines containing angelica sinensis appear to nourish and activate the blood and relieve pain by promoting coronary circulation.
An Adaptive Approach to Modern-day Research Needs
Why are Topical Hydrophilic Creams Attracting Attention?
By product, demand for topical hydrophilic creams is anticipated to surge impressively, attributed to its ease of application, cost-effectiveness and enhanced bioavailability. These creams impart moisture to prevent dry, rough, itchy and scaly skin. A market share of 33% is anticipated for hydrophilic creams in the long run.
Radiation treatment often eliminates moisture content from the skin, rendering it extremely dry and irritated, thus requiring high amounts of water to reduce this constant irritation. 3M Company, for instance, offers the CavilonTM Advanced Skin Protectant, comprising of a hydrophilic composition of elastomeric polymer and a non-stinging solvent.
Will Retail & Online Pharmacies Register High Radiation Dermatitis Treatment Product Sales?
By distribution channel, Fact.MR expects radiation dermatitis treatment product sales to expand swiftly across retail pharmacies, attributed to increased incidence of home-based and self-treating prescriptions across major regions. Furthermore, retail pharmacies are easily accessible to patients.
Simultaneously, online pharmacies are gaining more prominence, given that an increasing number of patients seek virtual alternatives amid increased penetration of digital literacy which has enhanced access to smart gadgets and the internet. Moreover, these channels offer high discounts and home delivery options, making them the go-to option for customers. Collectively, both channels will likely account for 45% of total revenue.
Prominent manufacturers of radiation dermatitis treatment products are concentrating on expanding their presence in wound care, attributed to the increased frequency of surgery induced wounds experienced while undergoing radiation treatment. Notable developments are as follows:
- In January 2021, Integra Lifesciences Holdings Inc. acquired ACell Inc. and its proprietary MatriStem UBMTM technology to further enhance its complex wound management solutions
- In 2019, Molnlycke Health Care AB collaborated with Zuellig Pharma to strengthen its advanced wound care solutions across South East Asia. This follows the successful acquisition of SastoMed in July 2018, augmenting Mölnlycke’s range of wound care solutions with SastoMed’s ground-breaking, oxygen-therapy based solutions for chronic wounds
Interested to Procure The Data
Radiation Dermatitis Treatment Market- Report Scope
|Historical Data Available for||2016-2020|
|Market Analysis||US$ Mn for Value & ‘000 Units for Volume|
|Key Regions Covered||
|Key Countries Covered||
|Key Segments Covered||
|Key Companies Profiled||
|Pricing||Available upon Request|
Key Segments Covered
- Oral Medication-based Radiation Dermatitis Treatment
- Oral Analgesics & Antibiotics
- Topical Radiation Dermatitis Treatment
- Hydrophilic Creams
- Topical Antibiotics
- Dressing-based Radiation Dermatitis Treatment
- No Sting Barrier Film
- Honey Impregnated Gauze
- Silicone Coated Dressing
- Oral Medication-based Radiation Dermatitis Treatment
- Radiation Dermatitis Treatment through Hospital Pharmacies
- Radiation Dermatitis Treatment through Retail Pharmacies
- Radiation Dermatitis Treatment through Online Pharmacies
- FAQs -
As of 2021, Fact.MR expects radiation dermatitis demand to reach US$ 429.7 Mn
From 2021-2031, radiation dermatitis treatment products sales will likely surge at a CAGR of 5%
As per Fact.MR’s analysis, the market for radiation dermatitis treatment is likely to be valued at US$ 700 Mn in 2031
From 2016-2020, radiation dermatitis treatment demand surged at around 4% CAGR
According to Fact.MR, radiation dermatitis treatment product sales are likely to surge at a CAGR of 5.3% until 2031
India is expected to emerge as the fastest growing landscape for radiation dermatitis treatment, registering a CAGR of 6%
China is anticipated to register a CAGR of 5.8% for radiation dermatitis treatment in the decade spanning from 2021-2031
Topical hydrophilic creams are the most sought after, registering a market share of 33%
Retail and online pharmacies will jointly account for 45% of total radiation dermatitis products sales
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.